Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine crossover trial in obsessive-compulsive disorder
RBR-6kmdtgbPhase 3Recruiting
- Sponsor
- Hospital Universitário Professor Edgard Santos
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of esketamine in obsessive compulsive disorder (OCD) (2 arms), sponsored by Hospital Universitário Professor Edgard Santos. Primary endpoint: Change in Yale-Brown Obsessive-Compulsive Scale I score. Started Mar 2022; status: recruiting.
02
Drugs
esketamine
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on RBR-6kmdtgb.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-6kmdtgb.